Literature DB >> 25326497

Is a picture really worth a 1000 words?

Elizabeth R Gerstner1.   

Abstract

Mesh：

Year:  2014        PMID： 25326497      PMCID： PMC4232093          DOI： 10.1093/neuonc/nou309

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  8 in total

1.  Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria.

Authors:  Alexander Radbruch; Kira Lutz; Benedikt Wiestler; Philipp Bäumer; Sabine Heiland; Wolfgang Wick; Martin Bendszus
Journal:  Neuro Oncol       Date:  2011-12-06       Impact factor: 12.300

2.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

3.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

4.  Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma.

Authors:  Martha Nowosielski; Benedikt Wiestler; Georg Goebel; Markus Hutterer; Heinz P Schlemmer; Günther Stockhammer; Wolfgang Wick; Martin Bendszus; Alexander Radbruch
Journal:  Neurology       Date:  2014-04-11       Impact factor: 9.910

5.  Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.

Authors:  P Kunkel; U Ulbricht; P Bohlen; M A Brockmann; R Fillbrandt; D Stavrou; M Westphal; K Lamszus
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

6.  FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.

Authors:  Christina Schaub; Susanne Greschus; Mirko Seifert; Andreas Waha; Elias Blasius; Katja Rasch; Christiane Landwehr; Frederic Mack; Niklas Schäfer; Moritz Stuplich; Sied Kebir; Belinda Vilz; Björn Scheffler; Jan Boström; Matthias Simon; Horst Urbach; Martin Glas; Ulrich Herrlinger
Journal:  Oncology       Date:  2013-09-05       Impact factor: 2.935

7.  Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption.

Authors:  J L Rubenstein; J Kim; T Ozawa; M Zhang; M Westphal; D F Deen; M A Shuman
Journal:  Neoplasia       Date:  2000 Jul-Aug       Impact factor: 5.715

8.  The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.

Authors:  Clifford R Jack; Matt A Bernstein; Nick C Fox; Paul Thompson; Gene Alexander; Danielle Harvey; Bret Borowski; Paula J Britson; Jennifer L Whitwell; Chadwick Ward; Anders M Dale; Joel P Felmlee; Jeffrey L Gunter; Derek L G Hill; Ron Killiany; Norbert Schuff; Sabrina Fox-Bosetti; Chen Lin; Colin Studholme; Charles S DeCarli; Gunnar Krueger; Heidi A Ward; Gregory J Metzger; Katherine T Scott; Richard Mallozzi; Daniel Blezek; Joshua Levy; Josef P Debbins; Adam S Fleisher; Marilyn Albert; Robert Green; George Bartzokis; Gary Glover; John Mugler; Michael W Weiner
Journal:  J Magn Reson Imaging       Date:  2008-04       Impact factor: 4.813
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.